| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Phosphodiesterase 5 (PDE5) (IC50 = 0.08 μM); Phosphodiesterase 1 (PDE1) (IC50 = 3.2 μM); Phosphodiesterase 3 (PDE3) (IC50 = 12.5 μM); Phosphodiesterase 4 (PDE4) (IC50 = 15.8 μM) [1]
|
|---|---|
| ln Vitro |
In isolated pig coronary arteries that have been precontracted with prostaglandin F2α (PGF2α; EC50=190 nM), MBCQ (compound 3d) causes relaxation [1]. MBCQ (0.01-10 μM; 10 min) suppresses the concentration-dependent contractions in rat ileal smooth muscle that are generated by carbachol (10 μM) [3].
MBCQ showed potent and selective inhibition of PDE5, with IC50 = 0.08 μM; it exhibited much lower potency against PDE1, PDE3, and PDE4 (IC50 > 3 μM) [1] - In isolated rat ileal smooth muscle strips pre-contracted with KCl (60 mM), MBCQ (1-100 μM) induced concentration-dependent relaxation: 10 μM caused ~35% relaxation, 30 μM caused ~62% relaxation, and 100 μM caused ~88% relaxation [3] - The relaxation effect of MBCQ (30 μM) on rat ileal smooth muscle was not affected by pretreatment with PDE inhibitors (IBMX) or cyclic nucleotide analogs (8-Br-cGMP, 8-Br-cAMP), indicating no dependence on cyclic nucleotide regulation [3] - In isolated rabbit corpus cavernosum smooth muscle pre-contracted with phenylephrine (1 μM), MBCQ (0.1-10 μM) induced relaxation with an EC50 of 0.8 μM; 10 μM caused ~90% relaxation [1] - In nitrate-tolerant rabbit aortic rings pre-contracted with phenylephrine (1 μM), MBCQ (1-10 μM) reversed tolerance and induced relaxation: 10 μM caused ~75% relaxation, compared to ~20% relaxation in tolerant rings without MBCQ [2] |
| ln Vivo |
In Sprague-Dawley rats rendered nitrate-tolerant by continuous infusion of nitroglycerin (10 μg/kg/min for 24 h), intravenous administration of MBCQ (1 mg/kg) significantly reversed venous nitrate tolerance: the venodilatory response to nitroglycerin (1 μg/kg, i.v.) was restored from 25% (tolerant control) to 78% (P<0.01) [2]
- MBCQ (1 mg/kg, i.v.) did not affect blood pressure or heart rate in nitrate-tolerant rats, indicating minimal cardiovascular side effects at therapeutic doses [2] |
| Enzyme Assay |
PDE activity assay: Recombinant human PDE subtypes (PDE1, PDE3, PDE4, PDE5) were purified and resuspended in assay buffer. MBCQ was serially diluted (0.001-100 μM) and mixed with each PDE subtype. The reaction was initiated by adding [3H]-cGMP (for PDE5, PDE1) or [3H]-cAMP (for PDE3, PDE4) as substrates. After incubation at 37°C for 30 minutes, the reaction was terminated by adding a PDE stop solution. Unhydrolyzed nucleotides were adsorbed onto anion-exchange resin, and the radioactivity of hydrolyzed products in the supernatant was measured by liquid scintillation counting. IC50 values were calculated by nonlinear regression of dose-response inhibition curves [1]
|
| Animal Protocol |
Nitrate tolerance model establishment: Sprague-Dawley rats were implanted with osmotic minipumps delivering nitroglycerin (10 μg/kg/min) for 24 h to induce venous nitrate tolerance. Control rats received vehicle via minipumps [2]
- Drug administration and assessment: Tolerant rats were randomly divided into MBCQ group and vehicle group (n=6/group). MBCQ (1 mg/kg) was administered via intravenous injection, and vehicle group received equal volume of saline. Thirty minutes later, nitroglycerin (1 μg/kg, i.v.) was injected, and venodilatory response was measured by sonomicrometry to assess reversal of tolerance [2] - Cardiovascular parameter monitoring: Blood pressure and heart rate were recorded via a carotid artery catheter before and after MBCQ administration to evaluate safety [2] |
| References |
|
| Additional Infomation |
N-(1,3-benzodioxanepenten-5-ylmethyl)-6-chloro-4-quinazolinamine is a quinazolinoid compound.
MBCQ is a quinazolinoid derivative whose 6-position substituent is crucial for its potent and selective PDE5 inhibitory activity[1] - MBCQ is characterized by a quinazolinoid core with a hydrophobic side chain at the 6-position, enabling it to have a high affinity for the PDE5 active site[1] - MBCQ induces relaxation of rat ileal smooth muscle through a cyclic nucleotide-independent mechanism, which differs from its PDE5 inhibitory effect in vascular tissue[3] - MBCQ selectively reverses intravenous nitrate tolerance by inhibiting PDE5 without affecting arterial response or causing hypotension, suggesting its potential application value in nitrate therapy. Angina tolerance[2] |
| Molecular Formula |
C₁₆H₁₂CLN₃O₂
|
|---|---|
| Molecular Weight |
313.74
|
| Exact Mass |
313.062
|
| CAS # |
150450-53-6
|
| PubChem CID |
6610310
|
| Appearance |
Off-white to yellow solid powder
|
| LogP |
3.697
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
386
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
CNODHOSDWZLJGA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12ClN3O2/c17-11-2-3-13-12(6-11)16(20-8-19-13)18-7-10-1-4-14-15(5-10)22-9-21-14/h1-6,8H,7,9H2,(H,18,19,20)
|
| Chemical Name |
4-((3,4-Methylenedioxybenzyl)amino)-6-chloroquinazoline 4-Quinazolinamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~318.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.97 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1874 mL | 15.9368 mL | 31.8735 mL | |
| 5 mM | 0.6375 mL | 3.1874 mL | 6.3747 mL | |
| 10 mM | 0.3187 mL | 1.5937 mL | 3.1874 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
